Targeting NEAT1 with antisense oligonucleotides or siRNAs, in combination with established mTOR inhibitors such as everolimus, represents a promising dual‐approach strategy for the treatment of TSC‐related epilepsy. Here, NEAT1 is linked to epilepsy.